ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) followed by circulating tumor DNA (ctDNA) analysis for tailoring targeted therapies.
Eligibility criteria
Qualifiers
Age 18 or older.
Able to do most daily activities (ECOG 0-2).
Able and willing to sign an informed consent form to join the study.
Metastatic non-small cell lung cancer (NSCLC) with either an EGFR mutation or ALK rearrangement confirmed by imaging and biopsy.
Disqualifiers
More than 5 extracranial sites of progressive disease.
Pregnant.
Leptomeningeal disease.
Serious health issues that prevent radiotherapy, like ataxia-telangiectasia or scleroderma.
Trial design
Treatments tested in this trial
- Radiotherapy
- Radiotherapy
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
1Radiation Medicine Program, Princess Margaret Cancer Centre, University Health NetworkM5G 2M9, TorontoOntario, Canada
Sponsors and collaborators
University Health Network, Toronto
Lead sponsor
Source ClinicalTrials.gov